Department of Clinical Laboratory, Peking University People's Hospital, Beijing, China.
Front Cell Infect Microbiol. 2022 Mar 25;12:818167. doi: 10.3389/fcimb.2022.818167. eCollection 2022.
The co-reactivation of cytomegalovirus (CMV) and Epstein-Barr virus (EBV) in patients undergoing hematopoietic stem cell transplantation (HSCT) has been found. Research has shown that the reactivation of CMV or EBV is closely related to poor HSCT outcomes. In this study, we describe the clinical characteristics of HSCT patients with co-reactivation of CMV and EBV. We retrospectively reviewed the medical records of 327 patients who underwent HSCT at the Peking University People's Hospital Institute of Hematology. Co-reactivation of CMV and EBV was observed in a total of 75 patients (22.9%) who also had a higher incidence of hemorrhagic cystitis (P=0.000). HSCT patients with CMV and co-reactivation of CMV and EBV had a significantly lower 1-year overall survival (OS; P=0.050). Further, COX regression analysis showed that viral infection was a risk factor for 1-year OS (HR, 12.625 for co-reactivation . no reactivation, p=0.021, and HR 13.580 for CMV reactivation . no reactivation, P=0.013). In conclusion, the patients with CMV reactivation had poorer outcome after HSCT regardless of EBV reactivation.
研究发现，造血干细胞移植（HSCT）患者的巨细胞病毒（CMV）和 EBV 会同时再激活。研究表明，CMV 或 EBV 的再激活与 HSCT 结局不良密切相关。本研究描述了 CMV 和 EBV 同时再激活的 HSCT 患者的临床特征。我们回顾性分析了北京大学人民医院血液病研究所 327 例 HSCT 患者的病历。共有 75 例（22.9%）患者同时出现 CMV 和 EBV 再激活，且这些患者出血性膀胱炎的发生率更高（P=0.000）。CMV 和 CMV 与 EBV 同时再激活的 HSCT 患者 1 年总生存率（OS）显著降低（P=0.050）。此外，COX 回归分析表明，病毒感染是 1 年 OS 的危险因素（CMV 再激活. 无再激活的 HR 为 12.625，p=0.021，CMV 再激活. 无再激活的 HR 为 13.580，P=0.013）。总之，无论 EBV 是否再激活，CMV 再激活的 HSCT 患者预后较差。
